SEATTLE — In this video, Esther M. Bowie, MD, discusses research presented at the ASRS meeting on the long-term efficacy of pegcetacoplan as well as late-breaking reports of ocular inflammation associated with the treatment.
“The open-label study basically showed that the pegcetacoplan did decrease geographic atrophy out to month 30,” Bowie, a professor of ophthalmology at the Penn State Health Milton S. Hershey Medical Center, said. “You had a greater decline if you use it monthly vs. every other month.”
However, Bowie noted late-breaking reports of ocular